Show simple item record

dc.contributor.authorDomenici, Giacomo
dc.contributor.authorEduardo, Rodrigo
dc.contributor.authorCastillo Ecija, Helena
dc.contributor.authorOrive Arroyo, Gorka
dc.contributor.authorMontero Carcaboso, Ángel
dc.contributor.authorBrito, Catarina
dc.date.accessioned2021-03-03T13:33:58Z
dc.date.available2021-03-03T13:33:58Z
dc.date.issued2021-02-19
dc.identifier.citationCancers 13(4) : (2021) // Article ID 879es_ES
dc.identifier.issn2072-6694
dc.identifier.urihttp://hdl.handle.net/10810/50444
dc.description.abstractEwing’s Sarcoma (ES) is the second most frequent malignant bone tumour in children and young adults and currently only untargeted chemotherapeutic approaches and surgery are available as treatment, although clinical trials are on-going for recently developed ES-targeted therapies. To study ES pathobiology and develop novel drugs, established cell lines and patient-derived xenografts (PDX) are the most employed experimental models. Nevertheless, the establishment of ES cell lines is difficult and the extensive use of PDX raises economic/ethical concerns. There is a growing consensus regarding the use of 3D cell culture to recapitulate physiological and pathophysiological features of human tissues, including drug sensitivity. Herein, we implemented a 3D cell culture methodology based on encapsulation of PDX-derived ES cell spheroids in alginate and maintenance in agitation-based culture systems. Under these conditions, ES cells displayed high proliferative and metabolic activity, while retaining the typical EWSR1-FLI1 chromosomal translocation. Importantly, 3D cultures presented reduced mouse PDX cell contamination compared to 2D cultures. Finally, we show that these 3D cultures can be employed in drug sensitivity assays, with results similar to those reported for the PDX of origin. In conclusion, this novel 3D cell culture method involving ES-PDX-derived cells is a suitable model to study ES pathobiology and can assist in the development of novel drugs against this disease, complementing PDX studies.es_ES
dc.description.sponsorshipThe iNOVA4Health Research Unit (UIDB/04462/2020), cofunded by Fundação para a Ciência e Tecnologia (FCT)/ Ministério da Ciência e do Ensino Superior (MCTES), through national funds, and by FEDER under the PT2020 Partnership Agreement, is acknowledged for financial support. AMC was supported by grants from ISCIII-FEDER (CP13/00189 and CPII18/00009).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/
dc.subjectEwing’s sarcomaes_ES
dc.subjectPDX-derived cellses_ES
dc.subjecttumour spheroidses_ES
dc.subject3D cultureses_ES
dc.subjectalginatees_ES
dc.subjectdrug assayses_ES
dc.titlePDX-Derived Ewing’s Sarcoma Cells Retain High Viability and Disease Phenotype in Alginate Encapsulated Spheroid Cultureses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2021-02-26T14:43:41Z
dc.rights.holder2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/2072-6694/13/4/879/htmes_ES
dc.identifier.doi10.3390/cancers13040879
dc.departamentoesFarmacia y ciencias de los alimentos
dc.departamentoeuFarmazia eta elikagaien zientziak


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Except where otherwise noted, this item's license is described as 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).